Phio Pharmaceuticals shares more than tripled after the company said it saw positive results from its Phase 1b trial for its cancer treatment PH-762. Shares were recently up more than 270% to $6. ...
Marlborough, Massachusetts--(Newsfile Corp. - January 16, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback